Home > Boards > US Listed > Biotechs > Ocugen, Inc (OCGN)

OCGN “Ocugen initiated with an Outperform at Noble

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
sgunderbarth Member Profile
 
Followed By 187
Posts 17,527
Boards Moderated 1
Alias Born 02/17/12
160x600 placeholder
sgunderbarth   Tuesday, 07/27/21 07:44:16 AM
Re: None
Post # of 4466 
OCGN “Ocugen initiated with an Outperform at Noble Capital”

Noble Capital analyst Robert LeBoyer initiated coverage of Ocugen with an Outperform rating and $15 price target. The company has in-licensed Covaxin, a whole-virion vaccine for Covid-19 that has advantages over the the current vaccines in use today, LeBoyer tells investors in a research note.

https://m.thefly.com/news-story/3341723/2021-07-26%2010:00:13/search

What we've got here...is failure to communicate. Some men you just can't reach...which is the way he wants it, well, HE GETS IT! And I dont like it anymore than you men.

*Contact your licensed financial advisor before entering the market.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences